Clinical Trials
96 trialsTesting the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Institutes of Health Clinical Center (CC)
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
National Cancer Institute (NCI)
CISTO
University of Washington
EV-309
Astellas Pharma Inc
Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
University of Alicante
A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
Novartis
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
P300
Pathos AI, Inc.
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
STRIKE-001
K36 Therapeutics, Inc.
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
National Institutes of Health Clinical Center (CC)
Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors
Dana-Farber Cancer Institute
CD70-targeted immunoPET Imaging of Kidney Cancer
RenJi Hospital
ACCEL
Eli Lilly and Company
PRIAM
The Netherlands Cancer Institute
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
City of Hope Medical Center
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Jinling Hospital, China
PROMOTE: Identifying Predictive Markers of Response for Genitourinary Cancer
University of California, San Francisco
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
Gender Related Coping and Survivorship for Genitourinary Cancers
Johns Hopkins University
Health Gatherings - For Your Health After Cancer
University of Miami
TURANDORELA
The Netherlands Cancer Institute
PREVENT-GU
Ottawa Hospital Research Institute
START-001
Marengo Therapeutics, Inc.
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
CYCLONE 3
Eli Lilly and Company
Clinical Significance of Adherent Perinephric Fat in Patients Undergoing Partial Nephrectomy
Centre of Postgraduate Medical Education
PROter
Advanced Accelerator Applications
SOGUGCOVID
Spanish Oncology Genito-Urinary Group
uTRACT
UroGen Pharma Ltd.
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
Algemeen Ziekenhuis Maria Middelares
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Poseida Therapeutics, Inc.
Impact of COVID-19 on GU Disease
Icahn School of Medicine at Mount Sinai
Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
Sharp HealthCare
CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
University Teaching Hospital Hall in Tirol
RCT_LiESWT
Regina Elena Cancer Institute
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
REMEDY
University Health Network, Toronto
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
Mayo Clinic
Immune PDX
Duke University
BANN
University Medical Center Groningen
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
Promontory Therapeutics Inc.
Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer
Steba Biotech S.A.
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group